{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:36:03Z","timestamp":1782779763823,"version":"3.54.5"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background and Aim<\/jats:title><jats:p>Few non-invasive models were established to identify patients with non-alcoholic steatohepatitis (NASH). Liver biopsy remains the gold standard in the clinic. Decreased serum ceruloplasmin (CP) is reported in patients with non-alcoholic fatty liver disease (NAFLD). We aimed to develop a non-invasive model incorporating CP for identifying NASH from NAFLD without type 2 diabetes mellitus (T2DM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 138 biopsy-proven patients with NAFLD without T2DM were enrolled. The CP ratio was calculated for standardization as the CP value divided by the lower limit of normal. The clinical, anthropometric, biochemical, and histological parameters were compared between the low and high CP ratio groups divided by the median value. Multivariate logistic regression analysis was performed to develop a model for identifying NASH in patients with NAFLD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The medians of the high (<jats:italic>n<\/jats:italic> = 69) and low (<jats:italic>n<\/jats:italic> = 69) CP ratio groups were 1.43 (1.28\u20131.61) and 1.03 (0.94\u20131.12), respectively. A comparison of the two groups showed that the severity of steatosis, hepatocellular ballooning, inflammation activity, fibrosis, and liver iron deposition decreased along with the CP ratio (<jats:italic>p<\/jats:italic> &amp;lt; 0.05). The median CP ratio of patients with NASH was significantly lower than those with NAFL [1.15 (1.01\u20131.41) <jats:italic>vs<\/jats:italic>. 1.33 (1.24\u20131.54), <jats:italic>p<\/jats:italic> = 0.001]. A novel model which consists of the CP ratio, BMI, and aspartate aminotransferase (AST) was developed. The AUCs of the model in discriminating NASH from NAFLD was 0.796 (0.694\u20130.899) and 0.849 (0.713\u20130.984) in the training and validation groups, and 0.836 (0.659\u20131.000), 0.833 (0.705\u20130.962), and 0.821 (0.612\u20131.000) in patients with normal serum alanine aminotransferase, AST, and both levels, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Decreased CP ratio is associated with more severe histological activity, a diagnosis of NASH, and hepatic iron deposition among patients with NAFLD without T2DM. The CP ratio model could be served as a non-invasive approach to identifying patients with NASH, which might reduce the need for liver biopsy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.900794","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T05:27:38Z","timestamp":1655702858000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["A Novel Non-Invasive Approach Based on Serum Ceruloplasmin for Identifying Non-Alcoholic Steatohepatitis Patients in the Non-Diabetic Population"],"prefix":"10.3389","volume":"9","author":[{"given":"Qingling","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peizhan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xizhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taotao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of non-alcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in non-alcoholic fatty liver vs. non-alcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Non-alcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/hep.23314","article-title":"Decreased survival of subjects with elevated liver function tests during a 28-year follow-up","volume":"51","author":"S\u00f6derberg","year":"2010","journal-title":"Hepatology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"9026","DOI":"10.3748\/wjg.v20.i26.8351","article-title":"Role of liver biopsy in non-alcoholic fatty liver disease","volume":"20","author":"Nalbantoglu","year":"2014","journal-title":"World J Gastroenterol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/hep.21223","article-title":"In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in non-alcoholic fatty liver disease","volume":"44","author":"Wieckowska","year":"2006","journal-title":"Hepatology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1572-0241.2006.01041.x","article-title":"Non-alcoholic fatty liver disease in severely obese subjects","volume":"102","author":"Gholam","year":"2007","journal-title":"Am J Gastroenterol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1471-230X-6-34","article-title":"Diagnostic value of biochemical markers (NashTest) for the prediction of non-alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease","volume":"6","author":"Poynard","year":"2006","journal-title":"BMC Gastroenterol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/j.1365-2036.2010.04480.x","article-title":"A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients","volume":"32","author":"Anty","year":"2010","journal-title":"Alimentary Pharmacol Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1159\/000517383","article-title":"Development and validation of a novel scoring system for non-invasive non-alcoholic steatohepatitis detection in bariatric patients","volume":"14","author":"Billeter","year":"2021","journal-title":"Obesity facts."},{"key":"B13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00702-007-0687-7","article-title":"Ceruloplasmin and what it might do","volume":"114","author":"Healy","year":"2007","journal-title":"J Neural Transm"},{"key":"B14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1023\/A:1020775101654","article-title":"Aceruloplasminemia, an inherited disorder of iron metabolism","volume":"16","author":"Miyajima","year":"2003","journal-title":"Biometals."},{"key":"B15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1146\/annurev.nutr.22.012502.114457","article-title":"Ceruloplasmin metabolism and function","volume":"22","author":"Hellman","year":"2002","journal-title":"Annu Rev Nutr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.3748\/wjg.v26.i27.3952","article-title":"Serum ceruloplasmin can predict liver fibrosis in hepatitis B virus-infected patients","volume":"26","author":"Kang","year":"2020","journal-title":"World J Gastroenterol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.clinre.2019.04.001","article-title":"Novel predictive models using serum ceruloplasmin levels for hepatic steatosis in patients with chronic hepatitis B infection","volume":"44","author":"Kang","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/MPG.0b013e31827aced4","article-title":"Levels of serum ceruloplasmin associate with pediatric non-alcoholic fatty liver disease","volume":"56","author":"Nobili","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1003100","DOI":"10.1371\/journal.pmed.1003100","article-title":"Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies","volume":"17","author":"Jarvis","year":"2020","journal-title":"PLoS Medicine."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.3390\/ijerph18105227","article-title":"Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic, and environmental risk factors","volume":"18","author":"Juanola","year":"2021","journal-title":"Int J Environ Res Public Health."},{"key":"B23","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2337\/dc20-S002","article-title":"Classification and diagnosis of diabetes","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"Bedossa","year":"2012","journal-title":"Hepatology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1034\/j.1600-0676.2003.00824.x","article-title":"Diagnosis and phenotypic classification of Wilson disease","volume":"23","author":"Ferenci","year":"2003","journal-title":"Liver Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v085.i08","article-title":"RandomizeR: an R package for the assessment and implementation of randomization in clinical trials","volume":"85","author":"Uschner","year":"2018","journal-title":"J Stat Softw."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"101145","DOI":"10.1016\/j.eclinm.2021.101145","article-title":"acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study","volume":"41","author":"Wu","year":"2021","journal-title":"EClinicalMedicine."},{"key":"B31","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/hep.22429","article-title":"Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes","volume":"48","author":"Fracanzani","year":"2008","journal-title":"Hepatology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/liv.12226","article-title":"Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)","volume":"33","author":"Verma","year":"2013","journal-title":"Liver Int."},{"key":"B33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/hep.27395","article-title":"The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease","volume":"61","author":"Maximos","year":"2015","journal-title":"Hepatology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.14309\/ajg.0000000000000388","article-title":"Histologic findings of advanced fibrosis and cirrhosis in patients with non-alcoholic fatty liver disease who have normal aminotransferase levels","volume":"114","author":"Gawrieh","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e001174","DOI":"10.1136\/bmjdrc-2020-001174","article-title":"Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels","volume":"8","author":"Zheng","year":"2020","journal-title":"BMJ Open Diabetes Res Care."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3390\/ijms17071089","article-title":"Liver fat measured by mr spectroscopy: estimate of imprecision and relationship with serum glycerol, caeruloplasmin and non-esterified fatty acids","volume":"17","author":"France","year":"2016","journal-title":"Int J Mol Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/ajg.2010.170","article-title":"A role for low hepatic copper concentrations in non-alcoholic fatty liver disease","volume":"105","author":"Aigner","year":"2010","journal-title":"Am J Gastroenterol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"129979","DOI":"10.1016\/j.bbagen.2021.129979","article-title":"Copper and lipid metabolism: a reciprocal relationship","volume":"1865","author":"Blades","year":"2021","journal-title":"Biochim Biophys Acta Gen Subj."},{"key":"B39","doi-asserted-by":"publisher","first-page":"14219","DOI":"10.1073\/pnas.1613628113","article-title":"In vivo bioluminescence imaging reveals copper deficiency in a murine model of nonalcoholic fatty liver disease","volume":"113","author":"Heffern","year":"2016","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B40","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1053\/j.gastro.2008.04.007","article-title":"Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease","volume":"135","author":"Aigner","year":"2008","journal-title":"Gastroenterology."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2174\/138945012802002320","article-title":"Aceruloplasminemia","volume":"13","author":"Kono","year":"2012","journal-title":"Curr Drug Targets."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1038\/sj.emboj.7601735","article-title":"Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin EMBO J","volume":"26","author":"De Domenico","year":"2007"},{"key":"B43","doi-asserted-by":"publisher","first-page":"G117","DOI":"10.1152\/ajpgi.00246.2015","article-title":"Iron overload results in hepatic oxidative stress, immune cell activation, and hepatocellular ballooning injury, leading to nonalcoholic steatohepatitis in genetically obese mice","volume":"310","author":"Handa","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"109633","DOI":"10.1016\/j.cellsig.2020.109633","article-title":"Ceruloplasmin suppresses ferroptosis by regulating iron homeostasis in hepatocellular carcinoma cells","volume":"72","author":"Shang","year":"2020","journal-title":"Cell Signal."},{"key":"B45","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3748\/wjg.v25.i5.521","article-title":"Iron and liver fibrosis: mechanistic and clinical aspects","volume":"25","author":"Mehta","year":"2019","journal-title":"World J Gastroenterol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2021.03.014","article-title":"Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD","volume":"75","author":"Corradini","year":"2021","journal-title":"J Hepatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.jnutbio.2015.04.009","article-title":"Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease","volume":"26","author":"Tallino","year":"2015","journal-title":"J Nutr Biochem."},{"key":"B48","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1016\/S0021-9258(18)68783-6","article-title":"Transcriptional regulation of ceruloplasmin gene expression during inflammation","volume":"263","author":"Gitlin","year":"1988","journal-title":"J Biol Chem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1194\/jlr.R067595","article-title":"The role of ER stress in lipid metabolism and lipotoxicity","volume":"57","author":"Han","year":"2016","journal-title":"J Lipid Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/B978-0-12-410502-7.00007-7","article-title":"Aceruloplasminemia: an update","volume":"110","author":"Kono","year":"2013","journal-title":"Int Rev Neurobiol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1042\/bj2820835","article-title":"Mechanisms of caeruloplasmin biosynthesis in normal and copper-deficient rats","volume":"282","author":"Gitlin","year":"1992","journal-title":"Biochem J."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.900794\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T05:27:41Z","timestamp":1655702861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.900794\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":51,"alternative-id":["10.3389\/fmed.2022.900794"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.900794","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]},"article-number":"900794"}}